• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Research

Independent equity research and analysis from our analyst team

Research

Independent equity research and analysis from our analyst team

Alexandria: Pojken har bastat även på Esplanaden
Research1 hour ago by
Sauli Vilén

Alexandria: Pojken har bastat även på Esplanaden

Alexandrias första del av året har varit mycket stark och våra vinstestimat har stigit kraftigt. I förhållande till de höjda estimaten är aktien förmånlig.

Alexandria Group
Atria: Värderingen sjönk till en förmånlig nivå, trots att inflationen tär
Research6/5/2026, 5:00 AM by
Rauli Juva, Pauli Lohi

Atria: Värderingen sjönk till en förmånlig nivå, trots att inflationen tär

I och med kursnedgången har företagets värdering (t.ex. 2026 P/E och EV/EBIT 9x) enligt vår mening tyngts ner till en förmånlig nivå.

Atria
Aspocomp omfattande analys: Ny tillväxtfas driven av stark efterfrågan
Extensive research6/4/2026, 3:48 PM by
Kaisa Vanha-Perttula

Aspocomp omfattande analys: Ny tillväxtfas driven av stark efterfrågan

Vi förväntar oss att vinsten kommer att göra en tydlig uppåtgående korrigering under de närmaste åren, men vi anser att en betydande del av denna utveckling redan är inprisad i aktien.

Aspocomp Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Metacon: Securing funding to fuel the next growth phase
Research6/4/2026, 5:57 AM by
Lucas Mattsson

Metacon: Securing funding to fuel the next growth phase

In our view, the recently announced capital raise reduces the financing risks and should give the company the runway to execute its order backlog and help convert parts of its sales pipeline, at least in the short term.

Metacon
Nightingale: Nightingale sings to a deaf market
Research6/4/2026, 6:36 AM by
Antti Siltanen

Nightingale: Nightingale sings to a deaf market

The low valuation compensates for the very high level of risk.

Nightingale Health
North Media (Investment Case): Improved Q1 profit, but lowered guidance ceiling
Research6/3/2026, 9:54 AM by
Jacob Frehr, Rasmus Køjborg

North Media (Investment Case): Improved Q1 profit, but lowered guidance ceiling

Today, we publish our updated North Media A/S investment case following the Q1 2026 report. North Media delivered improved Q1 profitability with EBIT rising to DKK 4m and EBITDA up 72%, though management cut the top end of 2026 guidance on a weak start in SDR and BoligPortal. The stock continues to trade at a significant discount to peers, as the large securities portfolio results in a very low implied EV, leaving the operating business valued at close to zero.

North Media
Martela: Flyttlasset lättade, men balansräkningen tyngs fortsatt
Research6/3/2026, 6:12 AM by
Thomas Westerholm

Martela: Flyttlasset lättade, men balansräkningen tyngs fortsatt

Vi har beaktat försäljningen av Martelas flyttjänstverksamhet i våra estimat, vilket höjde vårt rapporterade vinstestimat för innevarande år, men sänkte de operativa estimaten.

Martela
Herantis: Clarity on efficacy study details
Research6/3/2026, 8:21 AM by
Antti Siltanen

Herantis: Clarity on efficacy study details

The study will produce high-quality data on the safety of the Parkinson's disease drug candidate and preliminary data on its efficacy.

Herantis Pharma
Curasight (Investment Case): Four high-value read-outs on track for H2 2026
Research6/2/2026, 10:00 AM by
Michael Friis, Victor Skriver

Curasight (Investment Case): Four high-value read-outs on track for H2 2026

In connection with Curasight's Q1 2026 interim report, we have updated our Investment Case. Our investment case covers the key investment reasons, risks, and valuation perspectives.

Curasight
Lamor Q1'26: Guidning beroende av snabb återhämtning i orderingången
Research6/1/2026, 5:15 AM by
Thomas Westerholm

Lamor Q1'26: Guidning beroende av snabb återhämtning i orderingången

Lamors Q1-siffror var lägre än våra förväntningar, vilket särskilt berodde på en svag orderbok och svag nyförsäljning.

Lamor
ExpreS2ion (Investment Case): Q1 2026 - continued progress across pipeline and partner programmes
Research5/29/2026, 6:00 AM by
Michael Friis, Victor Skriver

ExpreS2ion (Investment Case): Q1 2026 - continued progress across pipeline and partner programmes

In connection with the Q1 2026 report, we have updated our investment case. Q1 2026 has moved ExpreS2ion meaningfully forward and further derisked the investment case, with continued positive ES2B-C001 read-outs, a redesigned and strengthened Phase I programme, and a completed rights issue potentially securing the company's path to the end-2026 Phase I read-out.

ExpreS2ion Biotech
Verkkokauppa.com: CMD påminde om företagets starka position online
Research5/29/2026, 5:45 AM by
Arttu Heikura

Verkkokauppa.com: CMD påminde om företagets starka position online

De finansiella målen förblev oförändrade på en övergripande nivå.

Verkkokauppa.com
CapMan extensive report: Scale-up time
Extensive research5/29/2026, 5:36 AM by
Sauli Vilén

CapMan extensive report: Scale-up time

CapMan is currently in the midst of the largest fundraising cycle in its history, and the success of this effort will largely determine the stock’s trajectory in the coming years. If the fundraising is successful, the share valuation is favorable.

CapMan
TORM (Investment case): Strong Q1, upgraded 2026 guidance and sector-leading dividend yield
Research5/28/2026, 9:06 AM by
Rasmus Køjborg, William Jørck

TORM (Investment case): Strong Q1, upgraded 2026 guidance and sector-leading dividend yield

Following TORM's Q1 2026 interim report, we have updated our investment case on the company. Our updated investment case covers the key investment reasons, risks, and valuation perspective relative to peers across the international product tanker space, including pure-play operators in the Nordics, the US and Southern Europe.

Torm
Framery Initiation of Coverage: Soundproof value creation
Extensive research5/28/2026, 9:34 AM by
Thomas Westerholm

Framery Initiation of Coverage: Soundproof value creation

Framery is the global market leader in soundproofed office pods, which are a growing category and which the company has been instrumental in shaping.

Framery Group
Verve Q1'26: First steps on campaign to rebuild trust
Research5/28/2026, 5:30 AM by
Christoffer Jennel

Verve Q1'26: First steps on campaign to rebuild trust

Verve's Q1 report was broadly in line with our cautious expectations, confirming a seasonally softer but stable start to the year.

Verve Group
Loihde: Tillbaka ombord på det trygga vinsttillväxttåget
Research5/27/2026, 6:30 PM by
Frans-Mikael Rostedt

Loihde: Tillbaka ombord på det trygga vinsttillväxttåget

KKV har godkänt det betydande företagsförvärvet av BLC Turva med måttliga och väntade eftergifter, vilket eliminerar den osäkerhet som varit förknippad med affären. Affären gör Loihde till Finlands största leverantör av säkerhetsteknik.

Loihde
Research5/26/2026, 5:36 AM by
Juha Kinnunen

Sammanfattning av rapportsäsongen Q1'26: Den genomsnittliga vinsttillväxten var fortfarande långt ifrån målet

Den genomsnittliga operationella vinsttillväxten för företagen på Helsingforsbörsen var betydligt lägre än förväntat under Q1, men den finska ekonomin verkar fortsätta att växa trots nya osäkerhetsfaktorer.

INVISIO (Investment case): Strongest Q1 ever, new product ramp-up and Coast Guard catch-up in focus
Research5/22/2026, 1:00 PM by
Rasmus Køjborg

INVISIO (Investment case): Strongest Q1 ever, new product ramp-up and Coast Guard catch-up in focus

Following INVISIO's Q1 2026 interim report, we have updated our investment case on the company. Our updated investment case covers the key investment reasons, risks, and valuation perspective relative to peers across Nordic/EU defense equipment, international defense communications, and audio/hearing protection.

INVISIO
BioPorto (Investment Case): Q1 2026, advancement on the three pillars central to the long-term potential
Research5/22/2026, 12:30 PM by
Michael Friis, Victor Skriver

BioPorto (Investment Case): Q1 2026, advancement on the three pillars central to the long-term potential

In connection with the publication of BioPorto's Q1 2026 interim results, we have updated our investment case. Our investment case covers the key investment reasons, risks, and valuation perspectives.

BioPorto